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DNA Sequence Variants of p53: Cancer and Aging
To the Editor:
p53 has a critical role in cell-cycle control. As such, it
has been identified as an important target in human car-
cinogenesis. However, since human p53 was cloned,
10 DNA-sequence polymorphisms have been identi-
fied (Matlashewski et al. 1987; Weston and Godbold
1997). The codon 72 polymorphism (arginine/proline:
G/C), the first to be described, has been the subject of
31 epidemiological case-control studies that have ex-
plored a potential association with cancer (Olschwang
et al. 1991; Weston et al. 1992, 1994, 1997; Zhang et
al. 1992; Kawajiri et al. 1993; Birgander et al. 1995,
1996b; Jin et al. 1995; Sja¨lander et al. 1995a, 1996a;
Wu et al. 1995; Murata et al. 1996; To-Figueras et al.
1996; Golovleva et al. 1997;Weston and Godbold 1997;
Yung et al. 1997; Hayes et al. 1998; Helland et al. 1998;
Hildesheim et al. 1998; Josefsson et al. 1998; Lanham
et al. 1998;Minaguchi et al. 1998; Rosenthal et al. 1998;
Storey et al. 1998; Tagawa et al. 1998; Wang-Gohrke
et al. 1998). Although they err on the side of caution
by citing Weston and Godbold (1997), Bonafe` et al.
(1999, p. 293), referring to the codon 72 polymorphism,
state that “overall, the available data in the literature
suggest that p53 variants may be considered as risk fac-
tors for some of the major neoplastic diseases in humans,
such as lung, colorectal, breast and cervical cancer and
are expected to affect survival.” With respect to codon
72, we contend that this is probably not the case. In the
available data, lung cancer is the subject of eight studies
(Weston et al. 1992, 1994; Kawajiri et al. 1993; Bir-
gander et al. 1995; Jin et al. 1995; Murata et al. 1996;
To-Figueras et al. 1996; Tagawa et al. 1998). Three stud-
ies claim a statistically significant association: in one
study, a subset analysis suggested a relationship in lung
cancer cases diagnosed at age !53 years (Jin et al. 1995);
in the other two, the allelic frequencies were almost iden-
tical (and the difference was not significant) between
cases and controls (Kawajiri et al. [1993] observed a
proline-allele frequency of .35 for controls and .36 for
cases [n = 347 and 328, respectively]). Murata et al.
(1996) observed a proline-allele frequency of .40 for
controls and .35 for cases (n = 152 and 191, respec-
tively), but associations of cancer risk were claimed on
the basis of higher numbers of homozygotes (Kawajiri
et al. 1993; Murata et al. 1996). One study (Kawajiri
et al. 1993) implicated proline; the other (Murata et al.
1996), arginine.
Most recently, the relationship between cervical can-
cer, human papillomavirus (HPV) infection, and inher-
itance of the arginine allele has received considerable
attention. The initial study, cited by Bonafe` et al. (1999),
showed a high degree of correlation between inheritance
of the arginine allele and cervical cancer risk when HPV
infection was present but not when it was absent (Storey
et al. 1998). There are now eight studies of cervical
cancer, but only one shows any association and seven
are null (Hayes et al. 1998; Helland et al. 1998; Hil-
desheim et al. 1998; Josefsson et al. 1998; Lanham et
al. 1998; Minaguchi et al. 1998; Rosenthal et al. 1998).
There are five breast cancer studies (Kawajiri et al. 1993;
Sja¨lander et al. 1996a; Weston et al. 1997; Helland et
al. 1998; Wang-Gohrke et al. 1998); only one reached
significance. Of the other published studies, a positive
association has been claimed in 0/2 for nasopharyngeal
cancer (Birgander et al. 1996b; Golovleva et al. 1997;
Yung et al. 1997), 0/4 for colon cancer (Olschwang et
al. 1991; Kawajiri et al. 1993; Jin et al. 1995; Sja¨lander
et al. 1995a), 0/2 for bladder/urologic cancer (Kawajiri
et al. 1993; Wu et al. 1995), 0/1 for acute myelogenous
leukemia (Zhang et al. 1992), and 1/1 for stomach can-
cer (Kawajiri et al. 1993). Again, for stomach cancer,
the allelic frequencies were not different for cases and
controls, and an association of cancer risk with the ar-
ginine variant was claimed on the basis of higher num-
bers of arginine homozygotes in cases (Kawajiri et al.
1993; this report used the same control group noted
above, and the proline-allele frequency in stomach can-
cer was .28 [ ]).n = 140
We contend, therefore, that the balance of the results
of human molecular epidemiological association studies
suggests that codon 72 allelism does not have an impact
on human cancer risk. Specifically, at most, only 6 of
31 positive associations have been reported, and none
have received consistent support in attempts to replicate
them (Kawajiri et al. 1993; Jin et al. 1995; Murata et
al. 1996; Sja¨lander et al. 1996a; Storey et al. 1998).
Moreover, there is no obvious, plausible biological basis
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Table 1
Simulated Relative-Risk Calculation for a Standard
Population of 1,000 Persons
No. of
Cancer
Deaths
No. of
Survivors Total
Proline-allele carriers 147 392 539
Arginine homozygotes 83 378 461
Total 230 770 1,000
NOTE.—On the basis of the control genotypic fre-
quencies reported by Bonafe` et al. (1999), a relative risk
of 1.5, and a cancer death rate of 23% (WHO 1987;
Lopez 1990), the frequency of proline-allele carriers in
survivors is .509 (a reduction of 3.0%). If the relative
risk is raised to 2.0, the frequency of proline-allele car-
riers in survivors is .491 (a reduction of 4.8%). This
model addresses only a role for p53 allelism in cancer
as a cause of death. If limited to the major neoplasms
indicated by Bonafe` et al. (1999) (lung, colon, breast,
and cervical), with a relative risk of 2.0, the frequency
of proline-allele carriers in survivors is .526 (a reduction
of only 1.3%). Also note that, if any association is lim-
ited to proline homozygotes, then, for a relative risk of
1.5, this fraction of the population would be expected
to drop from .088 to .076 (a reduction of 1.2%). Bonafe`
et al. (1999), in fact, observed a drop of 2.0%, from
.088 to .068.
Table 2
Power Calculations
OR
NO. OF CENTENARIANS REQUIRED FOR
HYPOTHESIS TESTING WHEN FREQUENCY
OF PROLINE-ALLELE CARRIERS ISa
3.0% 4.8%
1.5 4,091 2,588
2.0 1,589 1,001
a Percentages are derived from calculations in table 1.
for an association of cancer risk with the codon 72 poly-
morphism. The impact of proline on the tertiary struc-
ture of a protein is disruption of a-helices. A proline
residue resides at the monomeric position codon 71;
therefore, at codon 72 there is no obvious consequence
to proline.
Results were reported for p53, codon 72, genotype
frequencies in healthy Italian centenarians and younger
controls (Bonafe` et al. 1999). The expectation was of
allelic winnowing in the case of a codon 72 variant as-
sociated with cancer susceptibility and subsequent sur-
vival. The frequency of proline-allele carriers was .539
in controls and .506 in centenarians, 3.3% lower (and
the corresponding allelic frequency was 2.7% lower, but
the difference was not significant). We conjecture that
their comparison of centenarians ( ) with youngern = 176
controls ( ) is too crude to detect the predictedn = 204
allelic winnowing (Bonafe` et al. 1999). First, the cause
of death from cancer in the Italian population is ∼23%
(WHO 1987; Lopez 1990). Second, even though we do
not agree that there is good evidence for an association
between inheritance at codon 72 and cancer suscepti-
bility, because of the molecular epidemiological data re-
viewed above, let us assume that the proline variant
carries a relative risk of 1.5–2.0 (Kawajiri et al. 1993).
On the basis of this assumption we might expect a re-
duction of 3.0%–4.8% in proline-allele carriers as the
population ages (table 1 shows a simulated table2# 2
for a standard population of 1,000 persons, given a rel-
ative risk of 1.5 and a cancer death rate of 23% [WHO
1987; Lopez 1990]). In the letter by Bonafe` et al. (1999),
a reduction of 3.3% in the frequency of proline-allele
carriers among centenarians was reported. This reduc-
tion is consistent with their hypothesis, although the
authors suggest that it is not (Bonafe` et al. 1999). More-
over, our corresponding projected reduction in allelic
frequency is 2.8% for a relative risk of 1.5; Bonafe` et
al. (1999) observed a 2.7% reduction in frequency.
However, to have, at a significance level of .05, 80%
power to detect a 3.0%–4.8% reduction in the pre-
valence of proline-allele carriers, a minimum of
2,002–3,178 people would be needed, given a relative
risk of 2.0; and 5,176–8,182 would be needed, given a
relative risk of 1.5 (results of power calculations are
given in table 2).
Notwithstanding these conclusions and observations,
we believe that p53 allelism is an important cancer-sus-
ceptibility factor but that it is more complex than that
simply defined by the polymorphism at codon 72. A
series of studies by a Swedish group (Beckman et al.
1994; Birgander et al. 1995, 1996a, 1996b; Sja¨lander
et al. 1995a, 1995b, 1996a, 1996b) indicated that a
constellation of three p53 polymorphisms (intron 3, co-
don 72, and intron 6) constituted a haplotype predictive
of increased breast cancer risk (odds ratio [OR] = 2.9,
95% confidence interval [CI] = 1.4–6.3 [Sja¨lander et al.
1996a]). Haplotypes were deduced on the basis of pop-
ulation frequencies of the individual polymorphisms.
First, estimates of pairwise haplotype frequencies were
calculated, and extended haplotype frequencies were de-
duced from this information. A subsequent study ex-
amined the same question but used a PCR-basedmethod
for physical determination of the haplotypes (Weston et
al. 1997, 1998). The results of the latter study were
consistent with those reported in the study by Sja¨lander
et al. (1996a) (OR = 2.5, 95% CI = 1.3–4.8, in post-
menopausal women) and further implicated a specific
haplotype, designated “p531-2-1.” More recently, a third
study, estimating extended haplotypes of these three
polymorphisms in a German population, provided re-
sults consistent with an elevated breast cancer risk as-
sociated with inheritance of p531-2-1 (OR = 2.0, 95% CI
= 1.0–3.9 [Wang-Gohrke et al. 1998]). It is to be noted
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that this latest report has adopted an allelic nomencla-
ture different from that developed by Beckman et al.
(1994) and adopted by others (Sja¨lander et al. 1996a;
Weston et al. 1997, 1998).
The balance of the results of human breast cancer
studies of molecular epidemiological haplotype associ-
ation—specifically, three positive associations in three
studies—suggests that inheritance of the p531-2-1 haplo-
type does have an impact on human breast cancer risk
(Sja¨lander et al. 1996a; Wang-Gohrke et al. 1998; Wes-
ton et al. 1998). However, more research is needed to
resolve this question. In our laboratory, we have adopted
a complementary molecular epidemiological and basic-
science approach. First, we are trying again to replicate
the epidemiological studies of breast cancer, by using the
PCR-based physical haplotype method in a population-
based case-control study that has sufficient power. Sec-
ond, we have derived normal human mammary cell
strains with known haplotypes and plan to test their
response to suspect breast carcinogens.
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